MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1002/art.70280

Медицинская библиотека · Arthritis & rheumatology (Hoboken, N.J.) · 2026

Deucravacitinib in Active Psoriatic Arthritis: Efficacy and Safety up to 52 Weeks From the Randomized, Double-Blind, Phase 3 POETYK PsA-2 Trial.

Mease Philip J, Chandran Vinod, Armstrong April W, Blanco Ricardo, Ogdie Alexis, Siegel Evan L, Gottlieb Alice B, Zeng Xiaofeng, Thaçi Diamant, Kishimoto Mitsumasa, Schulze-Koops Hendrik, Kivitz Alan, Dokoupilová Eva, Morita Akimichi, Ruderman Eric M, Plewinski Michael, Wang Kejia, Sardinas Caroline, Vritzali Eleni, Vaile John, Deodhar Atul

СтатьяПеревод в очереди

Аннотация

OBJECTIVE

To assess the efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with psoriatic arthritis (PsA) who were naive to biologic disease-modifying antirheumatic drugs or received tumor necrosis factor inhibitors.

METHODS

In the 52-week (W), double-blind, placebo-controlled, phase 3 POETYK PsA-2 study (NCT04908189), patients were randomized 3:3:1 to deucravacitinib 6 mg daily, placebo, or apremilast 30 mg twice daily (safety reference arm) through W16. From W16 to W52, patients continued receiving deucravacitinib or apremilast or switched from placebo to deucravacitinib. The primary endpoint was American College of Rheumatology 20% improvement in response (ACR20) at W16. Secondary endpoints were analyzed per prespecified order to control for multiplicity.

RESULTS

Overall, 729 patients were randomized (312 deucravacitinib, 312 placebo, 105 apremilast). Significantly more patients achieved ACR20 at W16 with deucravacitinib versus placebo (54.2% vs 39.4%; P=0.0002); responses improved beyond W16 and were maintained through W52 (deucravacitinib-deucravacitinib, 62.2%; placebo-deucravacitinib, 67.3%). At W16, significant differences with deucravacitinib versus placebo were observed in hierarchal secondary endpoints of HAQ-DI, PASI-75, SF-36 PCS, and achievement of MDA. At W16, serious adverse events occurred in 1.0%, 1.9%, and 3.8% of patients with placebo, deucravacitinib, and apremilast, respectively. No new safety signals, deaths, or imbalances in cardiovascular events, malignancies, or opportunistic infections occurred through W52.

CONCLUSION

Deucravacitinib was well-tolerated in patients with PsA and demonstrated superior efficacy versus placebo across multiple clinical endpoints and patient-reported outcomes, including functional ability and quality of life. Clinical responses and patient-reported outcomes were maintained through week 52.

Для цитирования: Mease Philip J, Chandran Vinod, Armstrong April W, Blanco Ricardo, Ogdie Alexis, Siegel Evan L, Gottlieb Alice B, Zeng Xiaofeng, Thaçi Diamant, Kishimoto Mitsumasa, Schulze-Koops Hendrik, Kivitz Alan, Dokoupilová Eva, Morita Akimichi, Ruderman Eric M, Plewinski Michael, Wang Kejia, Sardinas Caroline, Vritzali Eleni, Vaile John, Deodhar Atul. Deucravacitinib in Active Psoriatic Arthritis: Efficacy and Safety up to 52 Weeks From the Randomized, Double-Blind, Phase 3 POETYK PsA-2 Trial.. Arthritis & rheumatology (Hoboken, N.J.). 2026. DOI: 10.1002/art.70280.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.